PHG has secured a >90% holding of NS Technologies


This article is from Unspecified for Health Care, Medical & Biotech

"MELBOURNE, TUESDAY 30 MARCH, 2021: Pharmachal Health Group (“PHG” or “Company”) is pleased to announce the achievement of a series of major milestones in March that fundamentally improve its position and will provide immense momentum for the back half of 2021. 

Increased Ownership Puts PHG in Control of NDDS Products

PHG has secured a >90% holding of NS Technologies, the development company holding the certified patents for the Nano Drug Delivery System (“NDDS”). Pharmachal had previously held unlimited rights to develop and sell products utilizing the NDDS methodology. The increased ownership position puts Pharmachal squarely in control of the pipeline of NDDS products it is developing. 

Final Commercial-Scale Trial Batch of NOPAYNE Initiated

PHG concurrently initiated the last commercial-scale trial batch of its NOPAYNE NDDS lidocaine spray, paving the way to submission to the Therapeutic Goods Administration (TGA) in mid-2021. Pharmachal has already successfully completed the first two stages of the ‘step-up’ process, confirming that NOPAYNE can be produced in 10-litre and 50-litre batches. The last commercial-scale batch will establish the Company’s ability to produce 100-litre batches using the specialised equipment it has developed. PHG aims to launch NOPAYNE in the Australian human and veterinary markets in the second half of 2021. 

Planning to Launch New OTC Dermal Products

Pharmachal plans to also launch three new over-the-counter dermal products during the April quarter, including a physio cream, a foot cream and a eucalyptus-honey ointment. Management is currently finalising the details of the first production run. These products will be available for domestic and international sale in as few as six to eight weeks."

  Please click on the link below to read the full announcement.   

Related Attachments

March 31st, 2021

PHG | Update 30 March 2021 ( 130.96 KB )